
    
      This is a 2-part, prospective, multicenter, observational study of patients with MPS II to
      characterize disease-related biomarkers in urine, blood and cerebrospinal fluid (CSF). Part 1
      will include MPS II patients who are 2 -10 years and Part 2 will include MPS II patients who
      are 2 -30 years old at the time of enrollment. All patients may be on approved therapies for
      MPS II; no investigational treatment will be administered.
    
  